Lax, I just had to respond - Dr Talpaz, Dr Cortez, etc. always supported the risk-benefit value of ponatinib. It's the FDA that was concerned, and yes, their opinion counts for a lot, but PLEASE stop claiming that the clinicians have a concern. Definitely not the leading CML experts.
Market Data 
Markets 
AI
